[Current therapeutic strategy for hemolytic anemia: paroxysmal nocturnal hemoglobinuria].
Jun-ichi
J
Nishimura
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000744:Anemia, Hemolytic, Autoimmune / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D015551:Autoimmunity; D017322:Clinical Trials, Phase II as Topic; D015195:Drug Design; D018380:Hematopoietic Stem Cell Transplantation; D006457:Hemoglobinuria, Paroxysmal / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D058990:Molecular Targeted Therapy; D000069283:Rituximab; D013156:Splenectomy
D000305:Adrenal Cortex Hormones; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab; C481642:eculizumab